Physician profile
Manmohan Singh
NPI 1205821337
$408,478.78
in general payments reported to CMS, 2019-2025
16 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $76K · 2021: $94K · 2022: $105K · 2023: $53K · 2024: $12K · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Travel and Lodging: $2,836 · Food and Beverage: $2,601 · Consulting Fee: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,595.00 |
| Travel and Lodging | $2,836.34 |
| Food and Beverage | $2,600.66 |
| Consulting Fee | $1,125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $198,081.23 | 2019-2024 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $92,902.97 | 2021-2025 | Vraylar |
| Allergan, INC. | $73,418.66 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39,683.51 | 2020-2024 | Caplyta |
| Axsome Therapeutics, INC. | $2,931.82 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $326.09 | 2020-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $253.96 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $243.66 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $204.32 | 2019-2022 | |
| Mdd US Operations, LLC | $119.38 | 2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $97.91 | 2019 | |
| Jazz Pharmaceuticals INC. | $61.75 | 2022 | |
| Idorsia Pharmaceuticals US INC | $57.40 | 2022 | |
| Lundbeck LLC | $35.45 | 2020-2021 | |
| Corium, LLC | $31.77 | 2023 | Azstarys |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $28.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manmohan Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.